Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Medivation, Inc.
Gilead is closely evaluating the situation for remdesivir in India as the country tackles shortages of the drug, which has several local licensees, with instances of black marketing adding to the local woes. The US firm clearly will not want any momentum towards possible compulsory licensing as initiated by Hungary and Russia, even as Indian firms have cut prices of the antiviral.
Caught in a ‘vaccine nationalism’ crossfire a year ago, CureVac is now well placed to become a commercial entity – just as long as its mRNA platform can deliver.
India clears Russian vaccine for restricted use, adding a third vaccine to its arsenal in the fight against COVID-19. One local expert highlights the vaccine’s “clever design” amid hopes that it will hold good against variants as well.
India stops remdesivir exports amid steep surge in COVID-19 cases, while licensees of Gilead’s antiviral take multiple measures to ramp up production to meet local demand. One badly affected state stresses the need to stem panic given the limitations of the treatment, even as some non-licensees of the drug apparently seek to contribute to supplies.